Archives: Month: August 2025
-
August 15, 2025
Your Voice Matters: Protect Access to Genomic Testing for DCIS Patients
Every year, 60,000 women in the U.S. are diagnosed with ductal carcinoma in situ (DCIS), considered the earliest non-invasive form of breast cancer. Many women with DCIS receive radiation therapy (RT) after surgery—but not all of them need it.
Genomic tests like DCISionRT help personalize care by providing biological insights that help patients and their doctors understand whether radiation therapy is likely to benefit them. With this information, women can make more informed decisions and potentially avoid unnecessary treatment and side effects.
